loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations

Open ICICI
3-in-1 Account

Manage your Savings, Demat and Trading Account conveniently at one place

+91

BLOG

Gland Pharma and Neuland Laboratories have entered a long-term strategic CDMO partnership

ICICIdirect Research 06 Aug 2026 DISCLAIMER

News: Gland Pharma and Neuland Laboratories have entered a long-term strategic CDMO partnership under which Gland will set up a dedicated sterile API manufacturing suite at its JNPC facility in Visakhapatnam to support Neuland's growing demand for sterile APIs used in microparticle depot products and other complex formulations. The cGMP-, USFDA- and EU-compliant facility will add around 1,400 kg of annual capacity, combining Neuland's complex API expertise with Gland's sterile manufacturing capabilities to provide integrated development, regulatory and commercial manufacturing services, while strengthening global supply resilience and expanding both companies' presence in the high-value sterile API CDMO market.

View: Going by the text of the agreement, the deal is for Neuland’s CDMO (CMS) business which stood at ₹ 1252 crore or ~60% of Neuland’s FY26 sales. This bodes well for Gland as it will create one more CDMO innovative niche (partnership model) besides Cenexi. We will get some more insights from Gland management in their Q1 earnings call.

Impact: Positive

Download ICICI Direct app

Invest, Track, and Manage your Portfolio Anytime, Anywhere

Download ICICI Direct app

Invest, Track, and Manage your Portfolio Anytime, Anywhere